SciSparc Ltd. Ordinary Shares - SPRC STOCK NEWS

SciSparc Ltd. (NASDAQ: SPRC) has received approval from the Soroka University Ethics Committee to conduct a clinical trial for its proprietary drug SCI-210, targeting Autism Spectrum Disorder (ASD). This trial aims to evaluate the safety, tolerability, and efficacy of SCI-210, a combination of cannabidiol and CannAmide™, compared to CBD monotherapy in 60 children over 20 weeks. The approval marks a significant milestone for SciSparc in its pursuit of developing effective treatments for pediatric patients with limited options.

SciSparc Ltd. (Nasdaq: SPRC) announced the appointment of Prof. Ciro Leonardo Pierri as a special advisor for MitoCareX Bio Ltd., its new joint venture focused on drug development for cancers and infectious diseases. Prof. Pierri, a biochemist from the University of Bari, Italy, brings expertise in structural biology and molecular modeling. The JV aims to explore mitochondrial carriers' roles in disease treatment, building on successful proof-of-concept experiments in the UK. SciSparc is engaged in cannabinoid-based drug development, targeting conditions like Tourette syndrome and Alzheimer’s disease.

SciSparc Ltd. (Nasdaq: SPRC) announced a review of potential strategic transactions aimed at maximizing shareholder value. The board is considering various options, including investments, acquisitions, partnerships, or licensing its technologies. CEO Oz Adler highlighted the company's strong cash position, allowing for exploration of external alternatives while continuing its existing business strategy. The firm remains focused on developing treatments for central nervous system disorders, including Alzheimer’s and Tourette syndrome, while adhering to FDA guidelines.

SciSparc Ltd. (NASDAQ: SPRC) announced positive initial pre-clinical results for a treatment for cocaine addiction using MEAI, a novel psychedelic molecule from Clearmind Medicine Inc. (CSE: CMND). The collaborative provisional patent application was filed to explore treatment potential based on SciSparc's CannAmide™ compound and Clearmind's MEAI. The trials indicated that MEAI could reduce cocaine's reward effects in rats, presenting a potential breakthrough in cocaine addiction treatment. The study was conducted by Professor Gal Yadid at Bar Ilan University.

SciSparc Ltd. (NASDAQ: SPRC) has completed a $10 million private placement priced at-the-market, facilitated by Aegis Capital Corp. as the exclusive placement agent. The company is focused on developing cannabinoid-based pharmaceuticals, including SCI-110 for Tourette syndrome and SCI-160 for pain management. These projects aim to target various ailments such as Alzheimer's and autism. The private placement reflects investor confidence in SciSparc's innovative drug development pipeline.

SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Clearmind Medicine Inc. to file a provisional patent for a treatment targeting cocaine addiction. This involves a combination of SciSparc's CannAmide™ and Clearmind's MEAI, addressing the significant issue of cocaine addiction affecting over 1.3 million Americans. Current statistics highlight more than 350,000 hospital visits annually linked to cocaine use and around 16,000 overdose deaths. The collaboration aims to explore potential therapeutic solutions for addictions, with ongoing efforts to strengthen their partnership.

SciSparc Ltd. (NASDAQ: SPRC) announced the closure of a private placement, securing approximately $10 million in gross proceeds from a single healthcare-focused institutional investor. The company issued 3,546,100 units at a price of $2.82 per unit, consisting of one ordinary share and two non-tradable warrants, each exercisable for an ordinary share at $2.57 for a total of 7,092,200 shares underlying the warrants. The warrants have a term of five years. Aegis Capital Corp. acted as the exclusive placement agent.

SciSparc Ltd. (NASDAQ: SPRC) has announced a collaboration with Polyrizon Ltd. to develop an innovative pain treatment using SciSparc's SCI-160 platform combined with Polyrizon's Trap and Target^TM technology. The goal is to create a proprietary intranasal formulation that maintains effective SCI-160 concentrations in the brain. SciSparc will pay up to $2,550,000 in development fees, plus royalties on product sales. Previous pre-clinical trials demonstrated SCI-160's efficacy and safety in pain management, with results comparable to high-dose morphine.

SciSparc Ltd. (NASDAQ: SPRC) announced a securities purchase agreement with a healthcare-focused investor, generating approximately $10 million in gross proceeds. The offering includes the issuance of 3,546,100 units, priced at $2.82 each, consisting of ordinary shares and warrants exercisable at $2.57. The transaction is set to close on or around June 1, 2022. Aegis Capital is the exclusive placement agent. The securities are being sold in a private placement and won't be registered under the Securities Act of 1933, requiring compliance with SEC regulations.